Amgen reported a solid quarter with a 21% increase in EPS and raised earnings guidance, reflecting strong performance in key products despite challenges with Aranesp and Prolia's FDA response. Managementâ€™s optimistic outlook and strategic initiatives likely bolster investor confidence in the short term.

[1]